Drugs / AAV5-hRKp.RPGR
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT06646289 | Oct 2024 → Oct 2030 expected | retinitis pigmentosa | Janssen Research & Development, LLC | Active not recruiting | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT05926583 | Sep 2023 → Jun 2027 expected | retinitis pigmentosa | Janssen Pharmaceutical K.K. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04794101 | Dec 2020 → Sep 2029 expected | retinitis pigmentosa | Janssen Research & Development, LLC | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04671433 | Dec 2020 → Sep 2024 | retinitis pigmentosa | Janssen Research & Development, LLC | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AAV5-hRKp.RPGR | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04671433 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “AAV5-RPGR vector” NCT04671433 ↗ |
| Route | Other | “Bilateral, sub-retinal administration of AAV5-hRKp.RPGR” NCT04671433 ↗ |